Bridge to Life Raises $110 Million to Make Hypothermic Oxygenated Perfusion the Standard of Care in Liver Transplantation and Beyond
PR Newswire
DULUTH, Ga., Aug. 12, 2026
Financing will further accelerate the already successful early commercial rollout of VitaSmart™ HOPE System Company also advancing an active organ viability assessment tool designed to raise industry standards with a validated biomarker that gives transplant centers the data to save more organs and lives Funds fuel Bridge to Life's multi-organ product pipeline and reinforce its market leadershipDULUTH, Ga., Aug. 12, 2026 /PRNewswire/ -- Bridge to Life™ Ltd., a market leader in organ preservation solutions and perfusion technologies, today announced the successful completion of a $110 million Series C and debt financing. The equity financing was led by new investor Soleus Capital, along with Lauxera Capital Partners and participation by Bridge to Life directors, officers, and employees; the debt financing was provided by Soleus Capital Credit Opportunities Fund. Proceeds will fuel the VitaSmart™ launch by expanding the field team and providing the working capital to reach every U.S. transplant center. The remaining funds will advance Bridge to Life's new product pipeline, including a proprietary viability assessment tool, broadening its organ preservation portfolio, and scaling global operations. Proceeds were also used to refinance the Company's credit facility with Perceptive Credit Funds, thereby significantly reducing the Company's outstanding leverage and lowering its interest rate, as Bridge to Life has evolved from early development stage to a fully commercial organization.
